Skip to main content
. 2023 Jul 16;15:17588359231187205. doi: 10.1177/17588359231187205

Figure 1.

Figure 1.

Summary of special populations who are potentially administered ICIs.

AIDs, autoimmune diseases; ECOG PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCV, hepatitis C virus; HSCT, hematopoietic stem cell transplantation; ICIs, immune checkpoint inhibitors; MOD, major organ dysfunction; PPIs, proton pump inhibitors; SOT, solid organ transplant; TB, tuberculosis; TETs, thymic epithelial tumors.